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Sepsis is a frequent cause of death in very-low-
birthweight infants and often results in neurological 
impairment. Its attributable risk of sequelae has not 
been systematically assessed. To establish an out-
come tree for mapping the burden of neonatal sep-
sis, we performed systematic literature searches to 
identify systematic reviews addressing sequelae of 
neonatal sepsis. We included cohort studies and per-
formed meta-analyses of attributable risks. Evidence 
quality was assessed using GRADE. Two systematic 
reviews met inclusion criteria. The first included nine 
cohort studies with 5,620 participants and five out-
comes (neurodevelopmental impairment, cerebral 
palsy, vision impairment, hearing impairment, death). 
Pooled risk differences varied between 4% (95% con-
fidence interval (CI):2–10) and 13% (95% CI:5–20). 
From the second review we analysed four studies with 
472 infants. Positive predictive value of neurodevel-
opmental impairment for later cognitive impairment 
ranged between 67% (95% CI:22–96) and 83% (95% 
CI:36–100). Neonatal sepsis increases risk of perma-
nent neurological impairment. Effect size varies by 
outcome, with evidence quality being low to very low. 
Data were used to construct an outcome tree for neo-
natal sepsis. Attributable risk estimates for sequelae 
following neonatal sepsis are suitable for burden esti-
mation and may serve as outcome parameters in inter-
ventional studies.
Introduction
Sepsis is a major cause of death in neonates [1]. The 
majority of sepsis episodes (> 80%) occurs in preterm 
neonates [2]. Among very low birth weight infants 
(VLBW; < 1,500g), rates of sepsis range between 11% 
and 46% [3]. Sepsis in this high-risk population is 
mostly acquired during hospital stay with a late onset 
beyond 48–72 hours of life. Early onset sepsis, which 
becomes apparent within the first 48–72 hours of life 
is ‘nosocomial’ in the sense that it occurs in the hospi-
tal but should not be considered healthcare-associated 
because its origin is linked to childbirth and/or mater-
nal-fetal transmission of pathogens [4,5].
Neonatal sepsis and systemic inflammatory response 
syndrome (SIRS) are associated with brain damage 
that results in disability, particularly among preterm 
and VLBW infants [6-9]. However, adverse neurological 
outcomes frequently occur in VLBW infants for reasons 
other than sepsis [10]. Therefore, the impact of health-
care-associated neonatal sepsis on adverse outcome is 
difficult to establish.
A European consortium, as part of a project initi-
ated and funded by the European Centre for Disease 
Prevention and Control (ECDC), recently developed an 
incidence- and pathogen-based approach for estimat-
ing the burden of communicable diseases expressed 
in Disability Adjusted Life Years (DALYs) [11]. Relevant 
health outcomes of communicable diseases are rep-
resented by outcome trees which map the weighted 
progressions of diseases over time by ordering the con-
ditional probabilities of associated health outcomes 
[11]. Outcome trees take into account probabilities and 
duration of health outcomes. The burden of healthcare-
associated infections (HAIs) was not yet addressed by 
ECDC for two reasons: (i) Patients with HAIs differ from 
the general population in terms of comorbidities [7] and 
may be different regarding other factors as for exam-
ple certain risk behaviour and social determinants; (ii) 
HAIs cannot be allocated to a specific pathogen, and 
thus the pathogen-based approach is not applicable.
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Statements about the burden of communicable dis-
eases must be based on evidence-based medicine 
principles as in other fields of medicine. Systematic 
reviews have become the gold standard of assessing 
the evidence in medicine but they are time consum-
ing and expensive. Systematic reviews of systematic 
reviews (so-called ‘umbrella reviews’) offer a time-sav-
ing alternative to identify and exploit the current state 
of evidence in a field [12,13]. The aim of the study was 
to identify the relevant sources for the construction 
of an evidence-based outcome tree for neurological 
sequelae due to healthcare-associated neonatal sep-
sis in VLBW infants by systematically identifying and 
analysing existing systematic reviews that addressed 
neurodevelopmental impairment during infancy. From 
a clinical perspective, we aimed at investigating the 
extent by which sepsis in VLBW infants causes neu-
rological impairments. Ultimately, the resulting out-
come tree will constitute the basis for the estimation 
of the burden of hospital-acquired neonatal sepsis 
expressed in disability-adjusted life years (DALYs), 
within the general framework of the ECDC Burden of 
Communicable Diseases in Europe project (BCoDE).
Methods
We followed the approach described by Whitlock et 
al. [14] and Robinson et al. [15] to identify and exploit 
existing systematic reviews by re-analysing their data. 
Our study was performed according to the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses statement (PRISMA) [16].
Identification of studies
In a first step, we performed a systematic review of sys-
tematic reviews (i.e. an umbrella review) on the associ-
ation between neonatal sepsis and neurodevelopment 
in later life. To identify relevant systematic reviews 
we performed a systematic literature search using 
MEDLINE, EMBASE and Cochrane Central Register of 
Controlled Trials (CENTRAL), without language restric-
tions (Box 1). All systematic reviews published from 1 
January 2000 until 25 September 2013 were eligible if 
meeting predefined inclusion criteria (see below).
A further search for planned, ongoing and published 
systematic reviews was performed in the Prospective 
International Register of Systematic Reviews 
(PROSPERO).
In a second step, we performed an umbrella review 
on the positive predictive value of neurodevelopmen-
tal impairment for later cognitive function. To iden-
tify appropriate systematic reviews, we performed 
a systematic literature search (date of last search: 2 
July 2014) using MEDLINE, EMBASE and the Cochrane 
Central Register of Controlled Trials (CENTRAL) (Box 2).
 
Electronic search was complemented by manually 
checking the reference lists of identified reviews and 
studies.
Study eligibility
In a first step, we searched for systematic reviews on 
the association between neonatal sepsis and neurode-
velopment in later life. These systematic reviews had 
to capture primary studies which fulfilled the following 
inclusion criteria: (i) study population had to be neo-
nates; (ii) the exposure had to be sepsis acquired in 
a healthcare setting; (iii) the comparator (or control) 
had to be participants without sepsis; (iv) the studies 
included had to be cohort studies or clinical trials; (v) 
the studies had to investigate at least one neurodevel-
opmental outcome during follow-up, and (vi) the stud-
ies had to be conducted in a healthcare setting within 
an upper-middle- or high-income country [17]. An expert 
panel discussed and agreed on the addressed out-
comes to be relevant (for names and affiliations of the 
members of the expert panel, see Acknowledgements).
In a second step, the systematic reviews were searched 
for positive predictive values of neurodevelopmental 
impairment for later cognitive function. To be eligible, 
Figure 1
Selection process for (panel A) systematic review of 
systematic reviews and (panel B) primary studies on 
neurological sequelae of neonatal sepsis, umbrella review 
on neurological sequelae of healthcare-associated sepsis in 
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a systematic review had to fulfil the following inclusion 
criteria: (i) participants of the included studies had to 
be infants (aged 1–6 years) at first examination; (ii) 
neurodevelopmental impairment had to be measured 
by the Bayley Scales of infant development [18] at first 
examination; (iii) cognitive function (intelligence quo-
tient) had to be measured by a standardised test (e.g. 
Wechsler Intelligence Scale [19]) at second (follow-up) 
examination; (iv) a positive predictive value or data 
allowing its calculation had to be reported in the review 
or in the studies analysed in the review.
Data extraction
Two independent reviewers (SH and TH) screened the 
systematic reviews, located the primary studies ana-
lysed in the reviews and extracted the following data: 
citation, study period, study design, demographics, 
sex, ethnicity, definition of sepsis, definition of out-
come, length of follow-up, number of exposed and 
non-exposed with outcome, test used for first and 
second examination, positive predictive value and 
prevalence of condition. Discrepancies between the 
reviewers were solved by discussion until a consensus 
was reached.
Risk of bias assessment
The assessment of multiple systematic reviews 
(AMSTAR) tool was used to determine the methodologi-
cal quality of the systematic reviews included [20]. Risk 
of bias in the included cohort studies was assessed 
using the Newcastle Ottawa Scale [21]. Following 
the suggestions of the Cochrane Collaboration, we 
assessed risk of bias separately for each outcome in 
each study [22]. For the studies reporting positive pre-
dictive values, the Scottish Intercollegiate Guidelines 
Network (SIGN) checklist for diagnostic accuracy stud-
ies was used to assess risk of bias [23]. The results of 
the risk of bias assessments were expressed in terms 
of ‘high risk of bias’, ‘low risk of bias’ and ‘unclear risk 
of bias’. All risk of bias assessments were conducted 
by two independent investigators (SH and TH).
Assessment of the quality of the body of 
evidence
We adapted the methodology of the Grading of 
Recommendations Assessment, Development and 
Evaluation (GRADE) working group to assess the qual-
ity of the body of evidence [24,25]. The GRADE meth-
odology was initially developed to assess intervention 
studies. According to GRADE, the quality of evidence 
indicates the extent to which one can be confident that 
the estimate of effect is correct. Taking into account 
the entire body of evidence on one outcome, four lev-
els of evidence quality are applied: + , very low; +  + , 
low; +  +  + , moderate; and +  +  +  + , high. Adapting the 
original GRADE approach and considering the proposal 
by Huguet et al. [26], all bodies of evidence were ini-
tially graded as high quality of evidence. Considering 
the following criteria led to decreasing evidence qual-
ity: (i) risk of bias, (ii) inconsistency, (iii) indirectness, 
(iv) imprecision and (v) publication bias (for details on 
the criteria, see [24].
Data synthesis
Extracted study characteristics and data were summa-
rised in tables, together with risk of bias assessments. 
For data synthesis, the following two effect measures 
were used:
•	 Risk differences were applied to calculate attribut-
able risk to sepsis exposure as follows: Using data 
of the individual studies we subtracted the absolute 
risk of developing sequelae in controls from the risk 
of developing sequelae in cases (infected minus 
uninfected and corresponding 95% confidence 
intervals).
Figure 2
Forest plot of risk differences of (panel A) impaired 
neurodevelopment (mental development index < 70) and 
(panel B) cerebral palsy in neonates with sepsis compared 
with those without sepsis, umbrella review on neurological 
sequelae of healthcare-associated sepsis in very-low-
birthweight infants, date of search 25 September 2013
A.
B. 
Overall  (I²=67.5%, p=0.003)
Chen et al. (2008) [38]
Friedman et al. (2000) [40]
Schlapbach et al. (2011) [43]
Hack et al. (2000) [39]
Göcer et al. (2011) [41]
Stoll et al. (2004) [7]
Msall et al. (1994) [42]
Addison et al. (2009) [37]
0.13 (0.05 to 0.20)
0.21 (-0.01 to 0.43)
0.29 (0.10 to 0.48)
0.06 (-0.03 to 0.14)
-0.10 (-0.23 to 0.04)
0.28 (0.07 to 0.50)
0.15 (0.12 to 0.18)
0.20 (0.03 to 0.37)
0.09 (-0.09 to 0.27)
Risk difference (95% CI)
0-0.502 0.502
Study
Decreased risk after sepsis Increased risk after sepsis
Decreased risk after sepsis Increased risk after sepsis
Overall  (I²=0.0%, p = 0.51)
Stoll et al. (2004) [7]
Shah et al. (2008) [8]
Addison et al. (2009) [37]
Schlapbach et al. (2011) [43]
0.08 (0.06 to 0.10)
0.09 (0.07 to 0.11)
0.04 (-0.02 to 0.11)
0.07 (-0.11 to 0.24)
0.06 (0.00 to 0.12)
0-0.245 0.245
Risk difference (95% CI)Study
CI: confidence interval; MDI: Mental Developmental Index.
Studies are ordered alphabetically by first author. The pooled risk 
differences (overall; diamonds) were calculated by means of 
a random-effects model. Ninety-five percent CIs are shown in 
parentheses and as horizontal bars.
Neurodevelopmental impairment was defined as having a MDI < 70 
[18].
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•	 Positive predictive values were used to estimate the 
probability that an individual with an adverse neu-
rodevelopmental outcome during infancy continues 
to suffer from impairment during later life. Positive 
predictive values were either taken directly from the 
publications or calculated using the reported data 
as follows: number of true positives divided by the 
sum of true positives and false positives.
Risk differences were pooled across the studies, using 
the ‘metan command’ in Stata (Stata 12, Stata Corp, TX, 
US). In the presence of heterogeneity, a random-effects 
model was used. Otherwise, study data were combined 
using a fixed-effects model. I2, a direct measure of 
inconsistency of study results in a meta-analysis, was 
used to quantify the extent of heterogeneity. I2 ranges 
from 0% to 100%, with 0% indicating no inconsistency. 
Because the numbers of studies were too small (< 10), 
publication bias was not investigated. Positive predic-
tive values were not pooled but rather presented as a 
range of values to account for heterogeneity [27].
Development of the outcome tree
The results of the systematic reviews were used to 
construct an outcome tree, based on the methodology 
described by Kretzschmar et al. [11]. An outcome tree 
maps the weighted progression of a disease over time 
by ordering the conditional probabilities of associated 
health outcomes. Blocks indicate health outcomes. 
Arrows indicate transition between outcomes (e.g. the 
transition from neurodevelopmental impairment to 
permanent cognitive impairment). Attributable risks 
(i.e. risk differences) that derived from the systematic 
review were attached to the respective blocks and 
arrows.
Results
Neurodevelopmental sequelae of neonatal 
sepsis
Our search identified a total of 207 titles (Figure 1A). 
After eliminating duplicates and screening of titles and 
abstracts four publications were left for full text evalu-
ation. Of these, only one systematic review fulfilled 
the inclusion criteria and thus, was eligible for further 
analysis [3], whereas the remaining three publications 
were not eligible [28-30]. This systematic review was 
of acceptable methodological quality (AMSTAR sum-
mary score: 7/11). The review included 17 original stud-
ies reporting data on neurodevelopmental sequelae 
of neonatal sepsis in VLBW infants. We screened the 
abstracts and full texts of these studies and identified 
nine of them to be eligible (see Figure 1B), whereas 
seven did not fulfil the inclusion criteria [6,31-36] and 
one citation could not be located in data banks or 
libraries.
All nine included studies [7,8,37-43] were cohort stud-
ies. Details are shown in Table 1. The studies included 
a total of 5,620 neonates born between 1983 and 2007 
and were conducted in six upper-middle and high-
income countries. Three studies provided data on 
infants with extremely low birth weight (ELBW; < 1,000g) 
[7,40,44]. A further three studies reported on neonates 
with VLBW [37,38,41], whereas the remaining three 
studies based their inclusion criteria on gestational 
age [8,42,43]. Eight studies provided a definition of 
neonatal sepsis that was based on clinical and/or 
laboratory parameters. One study did not provide a 
definition [41]. One study reported on invasive Candida 
spp. infections only [40]. Duration of follow-up varied 
between 12 and 52 months.
From the reported outcomes we considered the follow-
ing five outcomes as clinically relevant: neurodevelop-
mental impairment, cerebral palsy, vision impairment, 
hearing impairment and death. Neurodevelopmental 
impairment was defined as having a Mental 
Developmental Index (MDI) < 70 [18]. For vision and 
hearing impairment, varying definitions were used in 
the studies. According to the Newcastle-Ottawa Scale 
[21], three studies had high risk of bias, while the 
remaining six showed a low risk of bias (Table 1).
Figure 3
Forest plot of risk differences of (panel A) hearing 
impairment and (panel B) vision impairment in neonates 
with sepsis, compared with neonates without sepsis, 
umbrella review on neurological sequelae of healthcare-
associated sepsis in very-low-birthweight infants, date of 
search 25 September 2013]
Overall  (I²=63.2%, p=0.099)
Hack et al. (2000) [39]
Stoll et al. (2004) [7]
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Studies are ordered alphabetically by first author. The pooled risk 
differences (overall; diamonds) were calculated by means of 
a random-effects model. Ninety-five percent CIs are shown in 
parentheses and as horizontal bars.
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Figure 2A shows the results of the meta-analysis of 
risk differences for neurodevelopmental impairment in 
infants with neonatal sepsis, as compared with those 
without sepsis. Eight studies reported risk estimates. 
We calculated a statistically significant pooled risk 
difference of 13% (95% CI: 5–20), with a large and 
significant between-study heterogeneity. This het-
erogeneity was mainly due to the study by Hack et 
al. [44]. Excluding this study lowered heterogeneity 
(I2  = 32.6%; p = 0.18) but had only a small impact on 
the pooled risk difference (15%; 95%CI: 9–20%). Since 
the study by Friedman et al. [40] was the only study 
in which the exposure was non-bacterial (Candida 
spp.), further sensitivity analysis was performed with 
six studies [7,37,38,41-44]. The pooled risk difference 
(14%; 95%CI: 9 ̶ ̶–19%) did not differ largely from the 
estimate of the complete dataset, but showed lower 
heterogeneity (I2 = 26.1%; p = 0.24).
Figure 2B displays the single study estimates and the 
pooled risk difference for the outcome cerebral palsy, 
which was reported by four studies. Infants who expe-
rienced neonatal sepsis had an 8% (95% CI: 6–10) 
higher risk of developing cerebral palsy than those 
who did not. Study results were highly homogenous 
(I2 = 0%).
Only two studies reported data on hearing impairment 
(Figure 3A) and vision impairment (Figure 3B) following 
neonatal sepsis. While there was a significant effect on 
vision impairment (9%; 95% CI: 7–11), the risk differ-
ence for hearing impairment was smaller and not sig-
nificant (4%; 95% CI: -2 to 10).
Two studies analysed mortality in association with 
neonatal sepsis. From Friedman et al. [40] we could 
calculate a risk difference of 2% for invasive Candida 
spp. infection (95% CI: -13 to 17), while Msall et al. [42] 
provided data to calculate a risk difference of 14% for 
bacterial sepsis (95% CI: -5 ̶ to 33). Meta-analysis was 
not conducted because exposure and results were too 
heterogeneous.
Neither grouping of primary studies by birth weight, 
nor by publication date had an influence on risk differ-
ences of neurodevelopmental impairment or cerebral 
palsy. The number of studies was too small to allow 
stratified meta-analysis.
To systematically assess the quality of evidence for 
each outcome we applied the GRADE methodology. For 
neurodevelopmental impairment, the quality of the evi-
dence had to be graded down by three levels: (i) for 
serious risk of bias, (ii) for serious inconsistency due 
to widely differing point estimates of the single stud-
ies, and (iii) for serious imprecision due to a wide CI 
around the pooled estimate. Therefore, evidence qual-
ity was only ‘very low’ for this outcome. Regarding 
cerebral palsy, very serious risk of bias (grading down 
two levels) led to an evidence quality of ‘low’ for this 
outcome. For the outcome vision impairment, evidence 
quality was graded down to ‘moderate’ due to serious 
risk of bias. Accounting for serious risk of bias and seri-
ous imprecision, evidence quality was graded down to 
‘low’ for the outcome hearing impairment.
Predictive value of early neurodevelopmental 
impairment for later cognitive function
Our search identified three potentially eligible reviews. 
After title and abstract screening, only one publication 
remained for full text screening [45]. This systematic 
review fulfilled our inclusion criteria and was therefore 
used as a database for further analysis.
The review was of acceptable methodological quality 
(AMSTAR summary score: 7/11). It contained a total 
of 18 publications that reported data on the relation 
between MDI scores during the first three years of life 
and cognitive function measured later in life in VLBW 
infants. After abstract and full text screening, four 
studies were eligible for further analysis [39,46-48], 
whereas the remaining 14 did not meet the inclusion 
criteria [49-62].
All included studies were cohort studies. Details are 
shown in Table 2. Studies accumulated a total of 472 
infants of either VLBW (n = 2 studies) or ELBW (n = 2 
studies) who were born between 1977 and 2004 in 
three different high-income countries. All four studies 
used the Bayley Scale of infant development to assess 
the proportion of infants with neurodevelopmental 
impairment (i.e. MDI < 70) at 12 to 24 months, and re-
evaluated the study sample at 3.4 to 8.6 years of age, 
using three different test batteries. According to the 
SIGN50 checklist [23], all four studies had a low risk 
of bias.
Figure 4
Evidence-based outcome tree for neurological sequelae of 
neonatal sepsis, umbrella review on neurological sequelae 
of healthcare-associated sepsis in very-low-birthweight 


















Outcomes (e.g. neurodevelopmental impairment) are shown 
in blocks. Arrows represent transitions between outcomes. 




Characteristics of included studies on neurodevelopment after neonatal sepsis, umbrella review on neurological sequelae of 
healthcare-associated sepsis in very-low-birthweight infants, date of search 25 September 2013
Reference Location Birth year(s) Population Definition of sepsis Duration of follow-up n
a Risk of 
biasb
Addison et al. 
(2009) [37] US 1999–2001 VLBW




Chen et al. 
(2008) [38] Taiwan 1998–2005 VLBW





al. (2000) [40] Canada 1988–1996 ELBW
Positive-culture Candida spp. or supportive 
brain autopsy 24 months 299 Low
Göcer et al. 
(2011) [41] Turkey 2002 VLBW Not defined
33–45 
months 117 High
Hack et al. 
(2000) [44] US 1992–1995 ELBW Positive blood culture and clinical signs 20 months 221 Low
Msall et al. 
(1994) [42] US 1983–1986
23–28 
weeks GA
Positive blood culture and 14–21 days 
antibiotics 52 months 149 Low
Schlapbach et 
al. (2011) [65] Switzerland 2000–2007
24–28 
weeks GA
Positive blood culture and clinical 
signs and antibiotics for ≥ 5 days
18–24 
months 372 Low
Shah et al. 
(2008) [8] Australia 2001–2003
< 30 weeks 
GA
Positive blood 
culture and biomarker and antibiotics ≥ 5 days 24 months 192 High
Stoll et al. 
(2004) [7] US 1993–2001 ELBW




ELBW: extremely low birth weight; GA: gestational age; US: United States; VLBW: very low birth weight.
a Study size
b According to Newcastle-Ottawa scale [21]
Table 2
Characteristics of included studies on predictive value of early neurodevelopmental impairment for later cognitive function, 
umbrella review on neurological sequelae of healthcare-associated sepsis in very-low-birthweight infants, date of search 2 
July 2014
Reference Location Birth year(s) Population
Test at first 
examination








































































Scale (IQ < 70)
12 months 3.4 years 94 75% (35–97) 6% Low
CI: confidence interval; ELBW: extremely low birth weight; FSIQ: full-scale intelligence quotient; IQ: intelligence quotient; MDI: mental 
development index; MPC: mental processing composite; PPV: positive predictive value; US: United States; VLBW: very low birth weight.
a Study size.
b According to SIGN50 checklist [23].
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The positive predictive value, i.e. the probability of 
having a positive test result at the second examination 
when the first test result was positive, varied between 
37% (95% CI: 27–49) and 83% (95% CI: 36–100). 
Heterogeneity between estimates was mainly due to 
the study by Hack et al. [39], which was the only study 
that did not use an externally validated test battery to 
assess IQ at follow-up. Excluding their estimate from 
the study pool resulted in positive predictive values 
between 67% (95% CI: 22–96) and 83% (95% CI: 
36–100).
Outcome tree for neurological sequelae of 
neonatal sepsis
The results of the systematic review were used to 
develop the outcome tree (Figure 4). Risk differences 
obtained from meta-analyses were used to estimate 
the transitional probabilities for acquiring neurodevel-
opmental impairment, cerebral palsy, vision impair-
ment, hearing impairment and death after having 
experienced sepsis during neonatal life. Furthermore, 
we used the positive predictive values identified in the 
second systematic review to estimate the probability of 
having a permanently impaired cognitive function after 
early neurodevelopmental impairment.
Discussion
We developed an outcome tree for neurological seque-
lae of neonatal sepsis in VLBW infants using the meth-
ods of evidence-based medicine. Our study shows that 
4–14% of neurological sequelae in ELBW and VLBW are 
attributable to neonatal sepsis. Although this may be 
lower than anticipated in this high-risk group, about 
three-quarters of infants with early neurodevelopmen-
tal impairment suffer from persistent cognitive impair-
ment later in life. Evidence quality was low to very low, 
mainly due to high risk of bias in the single studies as 
well as imprecision of estimates.
Due to the inclusion criteria of the systematic review, 
primary studies which used different definitions of 
neonatal sepsis were analysed together. While some 
authors defined sepsis as culture-proven sepsis plus 
clinical signs [38,44], others applied a definition that 
included antibiotic treatment in addition to positive 
blood culture [37,42,43]. Moreover, one study did not 
provide any definition of neonatal sepsis [41]. Definition 
issues also applied for outcomes. Vision impairment 
was defined differently in the primary studies: while 
both studies defined vision impairment as uni- or bilat-
eral blindness, one study also allowed the need for 
corrective lenses [44]. To estimate the impact of defini-
tion of exposure and/or outcome on the associations 
of interest, a larger number of carefully conducted pro-
spective studies with subgroup analyses of sufficient 
power would be needed.
To assess attributable risk, we used the original data of 
the studies included in the systematic reviews to calcu-
late risk differences. This approach may not adjust for 
potential confounders, which might bias the relation 
between exposure and outcome. In nearly all analysed 
studies the infants with neonatal sepsis differed in a 
number of important prognostic variables from controls 
such as gestational age, birth weight and co-morbidi-
ties. While the original studies did adjust for such vari-
ables by applying multivariate analysis, we could not 
do the same because (i) potential confounders were 
Box 1
Search strategy for umbrella review on the association 
between neonatal sepsis and neurodevelopment in later 
life, date of search 25 September 2013
















#16 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 
OR #10 OR #11 OR #12) AND (#13 OR #14) AND #15
Filters: Publication date from 2000/01/01; Humans; “Medline” 
OR “systematic review” OR “meta-analysis” OR “intervention”
Box 2
Search strategy for umbrella review on the positive 
predictive value of neurodevelopmental impairment for 
later cognitive function, date of search 2 July 2014





#5 #3 OR #4
#1 AND #2 AND #5 (no filters)
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not uniform, (ii) some studies adjusted for variables 
which are not confounders for our purpose, and (iii) we 
have not had access to the original database with the 
individual data to do so. We therefore did not follow 
this approach any further, but considered the problem 
of confounding in the risk of bias assessments. The 
study by Hack et al. [44] on ELBW infants born between 
1992 and 1996 illustrates that confounding may be 
outcome specific and leads to surprising results. In 
this particular study, neonatal exposure to sepsis was 
associated with hearing impairment, but also with a 
lower likelihood of neurodevelopmental impairment. 
This may best be explained by confounding due to 
postnatal use of corticosteroids administered in that 
time period in neonates without symptoms of infection 
to prevent chronic lung disease. Among others, Yeh et 
al. were able to show the strong side effects of this 
therapeutic strategy on neurodevelopment when they 
evaluated long-term neurodevelopmental outcomes of 
children who had participated in a randomised con-
trolled trial on the effects of dexamethasone therapy 
[63]. As for the other studies, it was surprising to find 
that risk differences for neurodevelopmental impair-
ment and cerebral palsy following neonatal sepsis 
were similar across different settings. Grouping of 
studies by birth weight or year of publication did not 
reveal trends for risk differences. More studies would 
be needed to analyse whether they are independent of 
birth weight, gestational age, setting and time. It may 
be concluded, however, that the attributable risks can 
be used as endpoints for studies evaluating the effec-
tiveness of specific sepsis therapy. Further, it may be 
hypothesised that sepsis therapy has not, over the 
years, improved to a similar extent as overall neonatal 
intensive care.
For meta-analysis, we pooled the risk differences from 
the individual studies to arrive at a single measure of 
attributable risk for each outcome. Statistical pooling 
of risk differences has been reported to cause prob-
lems with consistency, with relative risk estimates 
(including odds ratios) being more consistent than risk 
differences [64]. For comparison, we pooled the esti-
mates of the calculated relative risks (data available 
upon request from the authors). Since this analysis did 
not detect less inconsistency we concluded pooling of 
risk differences to be an adequate approach.
Our study has several strengths. We based our analy-
ses on a comprehensive systematic review of system-
atic reviews. By using an outcome-focused approach, 
we were able to perform a detailed assessment of risk 
of bias and evidence quality, thereby emphasising the 
limitations of the current evidence base.
Limitations of our study mainly arise from the limita-
tions in the systematic reviews and primary studies 
included. In particular, risk of bias and imprecision of 
the reported estimates might limit the scientific and 
clinical value of the data summarised here. The search 
by Alshaikh et al. [3] was last performed June 2012. 
We did not conduct a more recent search for primary 
studies. Thus we may not exclude the possibility that 
more recent studies could have influenced our find-
ings. Our results may be further improved by using the 
primary datasets of the included cohort studies and 
then adjusting for confounders compiled throughout all 
studies, such as sex, birth weight and gestational age.
In conclusion, this systematic review of systematic 
reviews shows that VLBW infants with sepsis dur-
ing neonatal life have an increased risk of developing 
permanent neurological impairment during later life. 
The magnitude of this effect varies by outcome, while 
evidence quality was low to very low. To improve the 
evidence base, carefully planned and conducted pro-
spective studies are needed.
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